

Review Article

Diet and Cardiovascular Disease: Venous Thrombo-embolism

Abstract

Venous thromboembolism is responsible for considerable morbidity and mortality. It is estimated to be the second most common medical complication, the second most common cause of excess length of hospital stay, and the third most common cause of excess mortality. Recurrences are common. Anticoagulation is usually given for three months. However, inefficiency and major bleeding is often noted. External compression devices and balloon or direct thrombectomy and insertion of inferior vena cava filters are also available. Increasing data indicate that diet may play an important role in preventing VTE. Obesity, which is significantly related to diet, may contribute to 30% of all VTEs. Further, plant-based diets, such as the Mediterranean, prudent, and DASH diets are related to a lower incidence of VTE. This manuscript reviews the published literature on the relationship of various dietary components and dietary patterns, and their impact on the development and progression of VTE.

Keywords: diet, cardiovascular disease, venous thromboembolism, deep vein thrombosis, plant-based diet, red meat

Introduction

Venous thromboembolism (VTE) denotes both deep vein thrombosis (DVT), and pulmonary embolism (PE)^{1,2}. It is a major preventable and treatable cause of morbidity and mortality in hospitalized patients^{3,4}. It has an incidence rate > 100 per 100,000 person-years⁵. The first manifestation of VTE is often fatal PE⁶. It can be responsible for up to 10% of all in-hospital mortality^{6,7}. VTE can be provoked (60% to 75% of cases) by strong triggering or persistent risk factors⁸⁻¹⁰ or unprovoked or idiopathic (25%-40% of cases) in nature^{11,12}. The former is usually associated with trauma, cancer, pregnancy, long-term immobilization, obesity, or surgery, while the latter often occurs without warning or identifiable causes, and often outside of a medical setting. Lifestyle factors, including diet, are contributors to VTE¹³.

Venous thromboembolism is not a benign disease^{14,15}. It is estimated to be the second most common medical complication, the second most common cause of excess length of hospital stay, and the third most common cause of excess mortality³. More than half of the cases are provoked by hospitalization, and 24% of these are attributable to surgery¹¹. VTE is a major cause of death^{16,17}. It is estimated that in the US, an estimated 857,000 deaths from DVT, 370,000 from PE, and 52,000 with VTE deaths occur⁹. It is also estimated that >370,000 VTE-related deaths occur in Europe¹⁷. Because VTE disproportionately affects older patients, it is expected that these estimates will increase in the future as the global population ages³.

Recurrence is common¹⁹⁻²¹. They also face increased mortality^{22,23}. The short-term mortality rate is approximately 25%^{22,23}. There is an increased risk of recurrence of almost 10% per year for non-provoked VTE, with a case-fatality rate of 3.6% to 12%²⁴⁻²⁶. Recurrence, despite anticoagulation, may occur after major surgery, major trauma, acute illnesses such as heart failure or pneumonia or with active cancer. Overall, it is estimated that one-third of patients suffer recurrent VTE within 10 years^{27,28}. Current guidelines recommend anticoagulation treatment for 3 months after VTE²⁹. For patients with a provoked VTE, treatment is usually safely discontinued after three months³⁰. However, for patients with unprovoked VTE, the optimal length of treatment is not clear^{31,32}. These patients are also more prone to suffer from other cardiovascular events, and this incidence is higher than in the general population, without VTE³³.

It is recommended that patients with DVT should be initially treated with oral anticoagulants (including rivaroxaban, dabigatran, and apixaban), intravenous heparin in the hospital, or with subcutaneous low-molecular-weight heparin (LMWH) along with warfarin. However, anticoagulation is not completely safe - a recent meta-analysis indicated major and fatal bleeding rates of 1.8% and 0.2%, respectively. Elevation of the affected limb and application of warm compresses to the affected area also help. In patients where anticoagulation therapy is potentially harmful, external compression devices could be used for DVT prophylaxis and treatment. Surgical procedures include balloon or direct thrombectomy and insertion of inferior vena cava filters^{34,35}. Despite these measures, individuals may face increasing morbidity due to post-thrombotic syndrome³⁶. Symptoms include pain, swelling, and ulceration, and these can severely impact the patients' health quality of life³⁷. VTE is associated with an increase in the disability-adjusted life years⁵. It also increases the healthcare burden³⁸, with hospitalization³⁹, especially readmissions, being the primary cost driver⁴⁰. Virchow in 1856 suggested that venous thrombosis was the result of stasis, hypercoagulability, and endothelial dysfunction (commonly known as Virchow triad)⁴¹. Besides other lifestyles, diet can play an important role in mitigating these factors⁴²⁻⁴⁹.

Discussion

The effect of diet on DVT/VTE susceptibility has been known since World War 2 when food rationing (high-complex-carbohydrate, low-fat diet) resulted in a lower incidence of DVT/VTE in parts of Europe^{50,51}. A multitude of subsequent studies has suggested that obesity may contribute to 30% of all VTEs⁵². Further, data also suggests that higher intakes of fruits and vegetables, alcohol, vitamin E, vitamin B6, and fiber are inversely associated with VTE risk¹³. On the other hand, a Western dietary pattern with high intakes of red and processed meat and trans fatty acids increases the VTE risk by about 11%⁵². Predominantly plant-based diets, such as the Mediterranean (MedD)⁵³ and the prudent diet⁵⁴ appear to have protective effects on VTE. Dietary Approaches to Stop Hypertension diet (DASH) also appears to be somewhat helpful⁵⁵.

Obesity

Diet influences obesity⁵⁶⁻⁵⁸. Obesity (as defined by body mass index or BMI) is a well-established strong risk factor for VTE⁵⁶⁻⁵⁸. A BMI should ideally be between 18.5 kg/m² to 24.9

kg/m². A BMI of 25 kg/m² to 29.9 kg/m² is considered overweight, while at or >30 kg/m² is diagnosed as obese⁵⁹. An elevated BMI has been identified as a risk factor for VTE in several observational population- based studies^{60,61}. In the LITE (Longitudinal Investigation of Thromboembolism Etiology) study (a cohort of 20,914 individuals aged 45 and older without prior VT, a relationship with higher BMI and increased risk of unprovoked and provoked VTE was documented (Hazard Ratio [HR]=1.3)⁶². Gregson et al. analyzed data from the Emerging Risk Factors Collaboration (ERFC) and the UK Biobank studies and reported that a BMI >30 kg/m² consistently showed a positive, dose-response association with incidence of VTE⁶³. The HR was 1.47 in the UKB study for incident VTE per 1- SD higher body mass⁶³. In the ERFC study, the HR was 1.43 for fatal VTE per 1-SD higher body mass⁶³. Mahmoodi et al. calculated that obesity almost doubled the risk of VTE⁶⁴. It is estimated that obesity is responsible for 30% of all VTEs in the United States⁶⁵. Abdominal obesity (with or without BMI calculated obesity) is associated with a higher incidence of VTE⁶⁶. Abdominal obesity is ascertained by several anthropometric measurements⁶⁷. Waist circumference (WC) should ideally be <102 cm in males and <88 cm in females when measured to the nearest 0.1 cm at the umbilical level in a standing position⁶⁸. The waist-hip ratio is normally 0.85 or less for women and 0.9 or less for men⁶⁹. Less commonly used is the waist-height ratio – this is calculated by dividing the WC by height⁷⁰. A ratio > 0.5 is consistent with central obesity⁷⁰. Borch et al. in a study with 222 incident VTE cases and a median 12.3 years' follow-up time, found that WC was a better indicator of a higher risk of VTE when compared to BMI⁷¹. Yuan et al. estimated that although the population- attributable risk due to elevated BMI was 12.4%, it was much higher for a high WC - 23.7%⁷². The causal relationship between obesity and VTE has been confirmed with Mendelian randomization studies^{73,74}. Even patients with a diagnosis of being overweight (BMI 25 kg/m² to 29.9 kg/m²) show a higher risk for VTE (Odds Ratio=2.1)⁷⁵. Besides pre-existing excess body weight, weight gain also increases the risk of VTE. The Tromsø Study (n=1,802, with 302 incident VTEs over a median of 6 years) found that a greater weight gain (7.5–40.0 kg) was associated with a 1.92-fold higher risk of VTE when compared with those with no or a moderate (0–7.4 kg) weight gain⁷⁶. The harmful effect of weight gain on VTE was recently confirmed by the ARIC (Atherosclerosis Risk in Communities) study (9,710 participants with 529 incident VTEs over 9 years). This study found that a higher weight gain (>7.71 Kg) was associated with a 1.46-fold higher risk of incident VTE when compared with those whose weight gain was +1.81 to +1.36 kg⁷⁷.

Excess body weight is associated with venous stasis, venous damage, and varicosity⁷⁸. It is also associated with increased activity of the coagulation cascade⁷⁹ and decreased activity of the fibrinolytic cascade⁸⁰ and inflammatory factors⁸¹. Further, obesity also contributes to other chronic conditions such as hypertension, diabetes, hyperlipidemia, and cancer that increase VTE risk^{82,83}. Excess body weight may be more detrimental to females when compared with males^{84,85}. In a cohort study from the US National Hospital Discharge Survey, obese women had a greater risk of DVT than obese men⁸⁴. In the all-female Nurses' Health Study, obesity tripled the risk of unprovoked PE⁸⁵.

Fruits and Vegetables/Wholegrains/Fiber

A higher intake of fruit and vegetables is well known to be associated with lower total and cause-specific mortality, including a reduction in cardiovascular deaths⁸⁶. Although many studies have questioned the benefit of fruit and vegetable intake on VTE, data remains favorable for a higher intake of fruits and vegetables in protecting against VTE⁸⁷. The Longitudinal Investigation of Thromboembolism Etiology study (prospective study over 12 years, 14,962 middle-aged adults) showed that there was a 27% to 53% reduction in the risk of VTE when eating >2.5 servings per day of fruit and vegetables was compared with eating <2.5 servings per day⁸⁸. Bhooapat et al. reported (multivariate analysis) that eating fewer vegetables was associated with an odds ratio (OR) for venous thrombosis of 3.74⁸⁹. Violi et al. reported an inverse association between fruit and vegetable consumption and VTE risk⁹⁰. Yuan et al. observed an inverse between fruit and vegetable consumption and risk of pulmonary embolism⁹¹. Further, fruits and vegetable intake (rich in vitamin K) help improve anti-coagulation control^{92,93}. Some evidence suggests that elevated cholesterol increases the risk of VTE⁹⁴. Greatly increasing dietary fiber may help decrease cholesterol levels. Published data is, however, not strong on the VTE protective effects of a generous intake of whole grains or fiber⁹⁵.

Fish

The evidence linking fish consumption with a lower risk of cardiovascular disease is strong^{96,97}. A recent meta-analysis including 11 prospective cohort and 8 case-control studies totaling 408,305 participants proved the existence of an inverse association between fish intake and risk of acute coronary syndrome⁹⁶. A modest and inverse association between fish intake and cerebrovascular disease was also reported in another recent meta-analysis of 26 prospective cohort and 12 randomized trials totaling 794,000 participants⁹⁷. A similar inverse relationship was noted between fish intake and VTE⁹⁵. Lyn et al. found that eating ≥ 0.1 serving of fish per day (or ≥ 1 serving per week for quintiles 2 to 5) were associated with a 30% to 45% lower risk of VTE than eating <0.1 servings of fish per day⁹⁵. The benefit is probably due to the omega-3 fatty acids content of fish⁹⁸. Fish eaters also live a healthier lifestyle – they follow a healthier diet, spend more time exercising, and smoke less, and these may also influence the risk of VTE in this population. If these confounding factors are considered, the benefits of fish consumption on the risk of VTE are less significant⁹⁹.

Coffee/Tea/Chocolate

The data on coffee/tea/chocolate consumption and the risk of VTE is sparse. Lippi et al. reviewed three studies (two prospective and one case-control) and concluded that coffee intake in an amount ≥ 5 coffee cups per day may reduce VTE risk by 25%¹⁰⁰. There was some suggestion that lower amounts of intake may increase the risk when compared to abstainers. Overall, the data is too limited to ascribe a definite connection.

Alcohol

The association between alcohol consumption and venous thromboembolism (VTE) risk has been investigated by various observational studies with inconsistent results. Low to moderate alcohol consumption has been associated with a decreased risk of arterial thrombosis¹⁰¹. The association between alcohol consumption and VTE risk also has been investigated by various

observational studies. Some studies reported a reduced VTE risk associated with moderate alcohol intake^{102,103}. Moderate alcohol consumption was also related to a lower risk of VTE in a 2013 study¹⁰⁴. Moderate alcohol consumption might have antithrombotic effects¹⁰⁵⁻¹⁰⁷, although it is unclear whether these reported effects are due to ethanol or other compounds¹⁰⁸. A much more recent study did not find an inverse association¹⁰⁹.

Some researchers have reported a U-shaped relationship¹⁰⁴. Dimmitt et al. reported that alcohol intake was associated with factor VII, tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1)¹¹⁰. Mukamal et al. found that light-to-moderate alcohol intake was related to lower levels of coagulation factors, but higher consumption was related to impaired fibrinolytic potential, which implied a J- or U-shaped relationship between alcohol intake and hemostatic parameters¹¹¹. However, Chen et al. failed to find a U-shaped association¹¹².

Several studies have reported no association between alcohol intake and VTE¹¹³⁻¹¹⁶. A meta-analysis, involving almost 400 thousand participants and more than 10 thousand patients with VTE from 10 prospective studies (14 cohorts), concluded that alcohol intake was not associated with the risk of VTE overall¹¹². However, some studies have suggested that alcohol may have some protective effects against VTE in women^{102,103,117}. There is also some indication that wine may have some VTE protective benefits. In a prospective cohort study including 26,662 individuals, Hansen-Krone et al. found that wine consumption appeared to lower the risk of VTE¹¹⁸. This was also seen in a recent study by Yuan et al. for wine consumption and deep vein thrombosis¹¹⁹. It is unclear if this benefit is from resveratrol, which is present in red wine¹²⁰.

Finally, some studies indicate that acute alcohol intoxication may raise the risk of VTE¹²¹. Heavy alcohol consumption may induce endothelial dysfunction¹²² and influence coagulation, fibrinolysis, and platelet activities¹²³⁻¹²⁶. These actions may predispose individuals to thrombosis^{127,128}. In addition, alcoholism is pro-inflammatory¹²⁹ and this activates coagulation, and coagulation modulates the inflammatory activity¹³⁰. Overall, these alcohol-associated changes increase thrombus formation and the risk of VTE. Alcohol use has been associated with an increased risk of cancer¹³¹, and injuries¹³² and these increase the risk for VTE. A recent meta-analysis of 10 prospective studies with a total of 441,128 individuals and 10,221 VTE cases found no association of alcohol intake with VTE¹¹². Overall, the relationship between alcohol intake and increased risk of VTE is unclear.

Red Meat/Saturated Fats

In a prospective study over 12 years, 14,962 middle-aged adults participating in the Atherosclerosis Risk in Communities study were followed up for incident VTE. Individuals consuming >1.5 servings of red and processed meat per day had a 2 times higher risk of developing VTE than those consuming <0.5 servings per day⁹⁵. Unprocessed red and processed red meats are high in saturated fatty acids, which have been shown to increase platelet aggregation¹³³. Further, high intakes of unprocessed red and processed red meat consumption have been linked to increased risk of cancer and cardiovascular disease, both of which increase the risk of developing DVT¹⁰⁹.

Vitamins/Micronutrients

Lyn et al. found lower VTE risk with increasing dietary intake of vitamin B6, folate, and foods rich in these nutrients was associated with a lower VTE risk. They attributed this to their effect on homocysteine levels^{95,134,135}. However, supplementation with these micronutrients does not reduce the risk of incident or recurrent VTE^{136,137}. Vitamin E stands out as its supplementation has been shown to have anticoagulant effects^{138,139}. The only study, however, that demonstrated a clinical effect was a randomized 10-year clinical trial that showed that 600 IU vitamin E every other day reduced VTE 21% compared with placebo in healthy women (Women's Health Study)¹⁴⁰. Since this trial has not been replicated, vitamin E supplementation is not recommended at this time for the prevention of VTE. It has been noted in several studies that whole foods with vitamins and minerals are often beneficial while individual supplementation is not – likely due to synergistic effects occurring among foods and their nutritive and nonnutritive components¹⁴¹.

Special Diets

Epidemiological evidence suggests that a diet with ample fruits and vegetables and little meat may substantially reduce the risk of VTE by favorably affecting serum markers of hemostasis and inflammation. The Western diet is characterized by more frequent intake of red/processed meat, saturated fat, refined grains, and sugar and low intakes of fish, fruit, and vegetables¹⁴². It is associated with a higher risk of DVT. The ARIC study reported that there was a 60% increased risk for VTE in individuals with high adherence to the Western diet pattern⁹⁵. The MedD is characterized by a high intake of fruits, vegetables, legumes, monounsaturated fatty acids (essentially extra virgin olive oil), and a moderate intake of fish and wine¹⁴³. People eating MedD have a low intake of meat – meat intake is associated with gut microbiota-related overproduction of TMAO (trimethyl-amino-oxidase), that favors arterial thrombosis¹⁴⁴. Further, an elevated FVIIc, FVIIIc, and vWF, which are related to increased risk of VTE incidence^{145,146}, and elevated FVIIIc, which is related to recurrence¹⁴⁷, are favorably influenced by the MedD¹⁴⁸. In the Dutch component of the European Prospective Investigation into Cancer and Nutrition (cohort of 34,708 individuals, a 2- unit stronger MedD score was associated with 0.74- fold lower pulmonary embolism risk⁵³. Dietary Approaches to Stop Hypertension dietary pattern, which lowers blood pressure, also benefits VTE. A recent cohort study found that high adherence to this diet (slightly modified) was associated with a lower risk of VTE in 30,137 women and 36,193 men followed up for 17.3 years⁵⁵. The prudent diet had more vegetables, fruit, cooking/dressing oil, cereals and legumes, whole grains, nuts, rice/pasta, fish, low-fat dairy, poultry, and water¹⁴⁹. Although the "prudent" diet shares many common characteristics with the MedD, it does not include olive oil and wine. A recent cohort study revealed that high adherence to the prudent dietary pattern was associated with a reduced risk of VTE in 14,818 middle-aged adults followed up for approximately 22 years⁵⁴. The ARIC study reported a relative risk of noncancer VTE over 12 years of follow-up for the highest versus lowest quintile of the prudent dietary pattern hazard ratio was 0.69⁹⁵.

Conclusion

Venous thromboembolism is an important vascular disease growing research suggesting that unhealthy lifestyle risk factors may cause a considerable proportion of unprovoked VTE. It is

estimated that a reduction of obesity, physical inactivity, current smoking, and Western diet by 25% in the general population might reduce the incidence of unprovoked VTE by 12%. As noted earlier, obesity and a Western diet are the major modifiable risk factors. The protective role of plant-based is persuasive. The MedD and the prudent diet have favorable effects in lowering the incidence and recurrence of VTE.

References

1. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thrombosis and Haemostasis* 2000;83(5):657-60.
2. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism. *Journal of General Internal Medicine* 2006;21(7):722-7.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. *Chest*. 2008;133(6) Supl:381S–453S. doi: 10.1378/chest.08-0656.
4. Caprini JA. Identification of patient venous thromboembolism risk across the continuum of care. *Clin Appl Thromb Hemost*. 2011;17(6):590–599. doi: 10.1177/1076029611404217.
5. Heit J.A. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015; 12: 464-474.
6. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? *J R Soc Med*. 1989;82(4):203–205. doi: 10.1177/014107688908200407.
7. Caprini JA. Identification of patient venous thromboembolism risk across the continuum of care. *Clin Appl Thromb Hemost*. 2011;17(6):590–599. doi: 10.1177/1076029611404217.
8. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *PLoS Med*. (2012) 9:e1001275. doi: 10.1371/journal.pmed.1001275.
9. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139–e596.
10. Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015;12:464–474.
11. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*. (2002) 162:1245–8. doi: 10.1001/archinte.162.11.1245.

12. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. *Thromb Haemost.* (2005) 93:298–305. 10.1160/TH04-08-05066.
13. Yuan S, Bruzelius M, Håkansson N, Åkesson A, Larsson SC. Lifestyle factors and venous thromboembolism in two cohort studies. *Thromb Res.* 2021 Jun;202:119-124. doi: 10.1016/j.thromres.2021.03.024.
14. Heit J. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost.* (2005) 3:1611–7. 10.1111/j.1538-7836.2005.01415.x.
15. Silverstein M, Heit J, Mohr D, Petterson T, O'Fallon W, Melton L. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med.* (1998) 158:585–93. 10.1001/archinte.158.6.585.
16. Galson SK. The surgeon general's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. [Accessed January 31,2022]. Available from: <http://www.surgeongeneral.gov/news/2008/09/pr20080915.html>. <http://www.ncbi.nlm.nih.gov/books/NBK44178/>.
17. Heit JA, Cohen AT, Frederick A, Anderson FA, VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. *Blood (ASH Annual Meeting Abstracts)* 2005;106 Abstract 910.
18. Cohen AT, Agnelli G, Anderson FA, et al. VTE Impact Assessment Group in Europe (VITAE) Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. *Thromb Haemost.* 2007;98:756–764.
19. Carrier M, Gal G, Wells PS, Rodger MA. Systematic review: case- fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Annals of Internal Medicine* 2010;152(9):578- 89.
20. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. *Annals of Internal Medicine* 2007;147(11):766-74.
21. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. *Lancet* 2010;376:2032-9.
22. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. *Thrombosis and Haemostasis* 2002;88(3).407-14.
23. Ness IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thromboembolism: a population-based study. *Journal of Thrombosis and Haemostasis* 2007;5(4):692-9.
24. Carrier M, Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Annals of Internal Medicine* 2010;152(9):578-89.
25. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. *Annals of Internal Medicine* 2007;147(11):766-74.

26. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. *Lancet* 2010;376:2032- 9.
27. Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. *Circulation*. (2015) 131:29–322. 10.1161/CIR.000000000000152.
28. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. . 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *Kardiol Pol*. (2014) 72:997–1053. 10.5603/KP.2014.0211.
29. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e419S–e496S.
30. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. *Int J Gen Med*. 2017;10:87–94.
31. Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, et al. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. *Res Pract Thromb Haemost*. 2021 Feb 20;5(2):326-341. doi: 10.1002/rth2.12482.
32. Robertson L, Yeoh SE, Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. *Cochrane Database Syst Rev*. 2017 Dec 15;12(12):CD011088. doi: 10.1002/14651858.CD011088.pub2.
33. Noumegni SR, Hoffmann C, Tromeur C, Lacut K, Didier R, et al. Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies. *Thromb Res*. 2021 Jul;203:172-185. doi: 10.1016/j.thromres.2021.05.009.
34. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*. 2021;5(4):927-974. doi:10.1182/bloodadvances.2020003442.
35. Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. *Chest*. 2021 Dec;160(6):2247-2259. doi: 10.1016/j.chest.2021.07.056.
36. Leizorovicz A. Long- term consequences of deep vein thrombosis. *Haemostasis* 1998;28 Suppl 3:1-7.
37. Utne, K.K., Tavoly, M., Wik, H.S. et al. Health-related quality of life after deep vein thrombosis. *SpringerPlus* 5, 1278 (2016). <https://doi.org/10.1186/s40064-016-2949-z>.
38. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. *J Thromb Haemost*. 2015;13:1365- 1371
39. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. *Thromb Res*. 2016;137:3–10.

40. Fernandez, M., Hogue, S., Preblich, R., & Kwong, WJ. (2015). Review of the cost of venous thromboembolism. *ClinicoEconomics and Outcomes Research*, 7, 451-462. <https://doi.org/10.2147/CEOR.S85635>.
41. Virchow R. Neuer fall von todlichen: emboli der lungenarterie. *Arch Pathol Anat*. 1856; 10: 225–228.
42. Marckmann P, Sandstrom B, Jespersen J. Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. *Atherosclerosis*. 1990; 80: 227–233.
43. Miller GJ, Martin JC, Mitropoulos KA, Reeves BE, Thompson RL, Meade TW, Cooper JA, Cruickshank JK. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. *Atherosclerosis*. 1991; 86: 163–171.
44. Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, Cooper J. Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration. *Arterioscler Thromb*. 1994; 14: 214–222.
45. Mennen LI, Witteman JC, den Breeijen JH, Schouten EG, de Jong PT, Hofman A, Grobbee DE. The association of dietary fat and fiber with coagulation factor VII in the elderly: the Rotterdam Study. *Am J Clin Nutr*. 1997; 65: 732–736.
46. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med*. 1999; 340: 1449–1454.
47. Mezzano D, Leighton F, Martinez C, Marshall G, Cuevas A, et al. Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. *Eur J Clin Nutr*. 2001; 55: 444–451.
48. Tucker KL, Olson B, Bakun P, Dallal GE, Selhub J, Rosenberg IH. Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial. *Am J Clin Nutr*. 2004; 79: 805–811.
49. Miller GJ. Dietary fatty acids and the haemostatic system. *Atherosclerosis*. 2005; 179: 213–227.
50. Strom A. Examination into the diet of Norwegian families during the war-years 1942–45, *Acta Med Scand Suppl*, 1948, vol. 21.1(pg. 41-47),
51. Malmros H. *Acta Med Scand*. 1950. p. 137.
52. Aaron R. and Mary Cushman. Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time? *Journal of the American Heart Association*. 2020;9:e019395. <https://doi.org/10.1161/JAHA.120.019395>.
53. Hoevenaar-Blom MP, Nooyens ACJ, Kromhout D, Spijkerman AMW, Beulens JWJ, van der Schouw YT, Bueno-de-Mesquita B, Verschuren WMM. Mediterranean style diet and 12-year incidence of cardiovascular diseases: the EPIC-NL cohort study. *PLoS One*. 2012; 7:1–7.
54. S.Y. Yi, L.M. Steffen, P.L. Lutsey, M. Cushman, A.R. Folsom. Contrasting associations of prudent and western dietary patterns with risk of developing venous

- thromboembolism. *Am J Med.* Volume 134, Issue 6, June 2021, Pages 763-768.e3.
<https://doi.org/10.1016/j.amjmed.2021.01.016>
55. Yuan S, Bruzelius M, Håkansson N, Åkesson A, Larsson S.C. Lifestyle factors and venous thromboembolism in two cohort studies. *Thromb Res.* 2021.
 56. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. *Thromb Haemost.* 2003;89(3):493-8.
 57. Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. *Am J Cardiol.* 2004;93(2):259-62.
 58. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. *Circulation*, 2008, vol. 117 1(pg. 93-102.
 59. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation.* 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee
 60. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K. Anthropometry, body fat, and venous thromboembolism: a Danish follow- up study. *Circulation.* 2009;120:1850- 1857.
 61. Borch KH, Braekkan SK, Mathiesen EB, et al. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. *Arterioscler Thromb Vasc Biol.* 2010;30:121- 127.
 62. Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. *Thromb Res.* 2016; 144:127– 132.
 63. Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, et al. Emerging Risk Factors Collaboration . Cardiovascular risk factors associated with venous thromboembolism. *JAMA Cardiol.* 2019; 4:163–173.
 64. Mahmoodi BK, Cushman M, Anne Næss I, Allison MA, Bos WJ, et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta- analysis of prospective studies. *Circulation.* 2017; 135:7–16.
 65. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics; 2020.
<https://www.cdc.gov/nchs/products/databriefs/db360.htm>. Accessed October 10, 2020.
 66. Yuan S, Bruzelius M, Xiong Y, Håkansson N, Åkesson A, Larsson SC. Overall and abdominal obesity in relation to venous thromboembolism. *J Thromb Haemost.* 2021 Feb;19(2):460-469. doi: 10.1111/jth.15168.
 67. Staynor JMD, Smith MK, Donnelly CJ, Sallam AE, Ackland TR. DXA reference values and anthropometric screening for visceral obesity in Western Australian adults. *Sci Rep.* 2020 Oct 30;10(1):18731. doi: 10.1038/s41598-020-73631-x.

68. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nat Rev Endocrinol*. 2020;16(3):177-189. doi:10.1038/s41574-019-0310-7.
69. <https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Term=%22Waist-Hip+Ratio%22%5BMeSH+Terms%5D>.
70. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes Rev*. 2012 Mar;13(3):275-86. doi: 10.1111/j.1467-789X.2011.00952.x.
71. Borch KH, Braekkan SK, Mathiesen EB, et al. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. *Arterioscler Thromb Vasc Biol*. 2010;30:121- 127.
72. Yuan S, Bruzelius M, Xiong Y, Håkansson N, Åkesson A, Larsson SC. Overall and abdominal obesity in relation to venous thromboembolism. *J Thromb Haemost*. 2021 Feb;19(2):460-469. doi: 10.1111/jth.15168.
73. Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. *J Intern Med*. 2015; 277:573–584.
74. Lindström S, Germain M, Crous-Bou M, Smith EN, Morange PE, et al. INVENT Consortium . Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study. *Hum Genet*. 2017; 136:897–902.
75. Bhoopat L, Rojnuckarin P, Hiransuthikul N, Intragumtornchai T. Low vegetable intake is strongly associated with venous thromboembolism in Thai population. *Blood Coagul Fibrinolysis*. 2010 Dec;21(8):758-63. doi: 10.1097/MBC.0b013e3283403537.
76. Horvei LD, Brækkan SK, Hansen JB. Weight change and risk of venous thromboembolism: the Tromsø study. *PLoS One*. 2016; 11:e0168878.
77. French SA, Lutsey PL, Rosamond W, MacLehose RF, Cushman M, Folsom AR. Weight change over 9 years and subsequent risk of venous thromboembolism in the ARIC cohort. *Int J Obes (Lond)*. 2020. 32948842. <https://doi.org/10.1038/s41366-020-00674-5>.
78. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. *Arch Intern Med*, 2002, vol. 162 10(pg. 1182-1189).
79. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis, *Eur J Vasc Endovasc Surg*, 2007, vol. 33 2(pg. 223-233).
80. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. *Int J Obes Relat Metab Disord*. 2004;28(11):1357-64.
81. Mahmoodi BK, Cushman M, Anne Næss I, Allison MA, Bos WJ, Brækkan SK, Cannegieter SC, Gansevoort RT, Gona PN, Hammerstrøm J, et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta- analysis of prospective studies. *Circulation*. 2017; 135:7–16.
82. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. *Circulation*. 2008;117:93–102.

83. Wolin KY, Carson K, Colditz GA. Obesity and cancer. *Oncologist*. 2010;15(6):556-65. doi: 10.1634/theoncologist.2009-0285.
84. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. *Am J Med*. 2005; 118: 978–980.
85. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. *JAMA*. 1997; 277: 642–645.
86. Wang DD, Li Y, Bhupathiraju SN, Rosner BA, Sun Q, Giovannucci EL, et al. Fruit and Vegetable Intake and Mortality: Results From 2 Prospective Cohort Studies of US Men and Women and a Meta-Analysis of 26 Cohort Studies. *Circulation*. 2021 Apr 27;143(17):1642-1654. doi: 10.1161/CIRCULATIONAHA.120.048996.
87. Gaston S. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. US Department of Health and Human Services. <http://www.surgeongeneral.gov/topics/deepvein/>.
88. Steffen L.M. Folsom A.R. Cushman M. Jacobs Jr., D.R. Rosamond W.D. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. *Circulation*. 2007; 115: 188-195.
89. Bhoopat L, Rojnuckarin P, Hiransuthikul N, Intragumtornchai T. Low vegetable intake is strongly associated with venous thromboembolism in Thai population. *Blood Coagul Fibrinolysis*. 2010 Dec;21(8):758-63. doi: 10.1097/MBC.0b013e3283403537.
90. F. Violi, D. Pastori, P. Pignatelli, R. Carnevale. Nutrition, thrombosis, and cardiovascular disease. *Circ Res*, 126 (2020), pp. 1415-1442.
91. Shuai Yuan, Maria Bruzelius, Scott M. Damrauer et al. Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies. *Nutrition, Metabolism and Cardiovascular Diseases*. Volume 31, Issue 10, 22 September 2021, Pages 2831-2838 <https://doi.org/10.1016/j.numecd.2021.06.021>.
92. Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. *Br J Haematol*. 2010;149(4):598-605.
93. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. *J Thromb Haemost*. 2007;5(10):2043-8.
94. Kawasaki T, Kambayashi J, Ariyoshi H, et al. Hypercholesterolemia as a risk factor for deep-vein thrombosis. *Thromb Res*. 1997;88(1):67-73.
95. Lyn M. Steffen, Aaron R. Folsom, Mary Cushman, David R. Jacobs Jr, and Wayne D. Rosamond. Greater Fish, Fruit, and Vegetable Intakes Are Related to Lower Incidence of Venous Thromboembolism. The Longitudinal Investigation of Thromboembolism Etiology. *Circulation*. 2007;115:188–195. <https://doi.org/10.1161/CIRCULATIONAHA.106.641688>.
96. Leung Yinko, SS, Stark, KD, Thanassoulis, G, Pilote, L. Fish consumption and acute coronary syndrome: a meta-analysis. *Am J Med*. 2014;127(9):848–857.
97. Chowdhury, R, Stevens, S, Gorman, D. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. *BMJ*. 2012;345:e6698.

98. Zhang Y, Ding J, Guo H, Liang J, Li Y. Associations of Fish and Omega-3 Fatty Acids Consumption With the Risk of Venous Thromboembolism. A Meta-Analysis of Prospective Cohort Studies. *Front Nutr.* 2020 Dec 17;7:614784. doi: 10.3389/fnut.2020.614784.
99. Mattiuzzi C, Cervellin G, Franchini M, Lippi G. Fish Intake and Venous Thromboembolism: A Systematic Literature Review. *Clin Appl Thromb Hemost.* 2016 May;22(4):309-13. doi: 10.1177/1076029615585992.
100. Lippi G, Mattiuzzi C, Franchini M. Venous thromboembolism and coffee: critical review and meta-analysis. *Ann Transl Med.* 2015;3(11):152. doi:10.3978/j.issn.2305-5839.2015.06.14.
101. Lee KW, Lip GYH. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. *Arch Intern Med.* (2003) 163:2368–92. 10.1001/archinte.163.19.2368.
102. Lindqvist PG, Epstein E, Olsson H. The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. *Br J Haematol.* (2009) 144:234–40. 10.1111/j.1365-2141.2008.07460.x.
103. Lutsey PL, Steffen LM, Virnig BA, Folsom AR. Diet and incident venous thromboembolism: the Iowa Women's Health Study. *Am Heart J.* (2009) 157:1081–7. 10.1016/j.ahj.2009.04.003.
104. Gaborit F.S. Overvad K. Nørgaard M. Kristensen S.R. Tjønneland A. Severinsen M.T. Alcohol intake and risk of venous thromboembolism. A Danish follow-up study. *Thromb Haemost.* 2013; 110: 39-45.
105. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review, *Arch Intern Med*, 2003, vol. 163 19(pg. 2368-2392).
106. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors, *BMJ*, 1999, vol. 319 7224(pg. 1523-1528).
107. Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort, *Circulation*, 2001, vol. 104 12(pg. 1367-1373).
108. Grønbaek M. Alcohol and cardiovascular disease: more than one paradox to consider. Type of alcoholic beverage and cardiovascular disease—does it matter?, *J Cardiovasc Risk*, 2003, vol. 10 1(pg. 5-10).
109. Lippi G. Mattiuzzi C. Franchini M. Alcohol consumption and venous thromboembolism: friend or foe?. *Intern Emerg Med.* 2015; 10: 907-913.
110. Dimmitt SB, Rakic V, Puddey IB, Baker R, Oosttryck R, Adams MJ, et al. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial. *Blood Coagul Fibrinolysis.* (1998) 9:39–45. doi: 10.1097/00001721-199801000-00005.
111. Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. *Circulation.* (2001) 104:1367–73. 10.1161/hc3701.096067.

112. Chen M, Ji M, Chen T, Hong X, Jia Y. Alcohol Consumption and Risk for Venous Thromboembolism: A Meta-Analysis of Prospective Studies. *Front Nutr*. 2020 Apr 2;7:32. doi: 10.3389/fnut.2020.00032.
113. Steffen L, Folsom A, Cushman M, Jacobs D, Rosamond W. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology. *Circulation*. 2007;115(2):188–195. doi: 10.1161/CIRCULATIONAHA.106.641688.
114. Hansen-Krone JJ, Brækkan SK, Enga KF, Wilsgaard T, Hansen J-B. Alcohol consumption, types of alcoholic beverages and risk of venous thromboembolism - the Tromsø Study. *Thromb Haemost*. (2011) 106:272–8. 10.1160/TH11-01-0043.
115. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. *Circulation*. (2010) 121:1896–903. 10.1161/CIRCULATIONAHA.109.921460.
116. Varraso R, Kabrhel C, Goldhaber SZ, Rimm EB, Camargo CA, Jr. Prospective study of diet and venous thromboembolism in US women and men. *Am J Epidemiol*. (2012) 175:114–26. 10.1093/aje/kwr377.
117. Pomp ER, Rosendaal FR, Doggen CJM. Alcohol consumption is associated with a decreased risk of venous thrombosis. *Thromb Haemost*. (2008) 99:59–63. 10.1160/TH07-07-0470.
118. Hansen-Krone I.J. Brækkan S.K. Enga K.F. Wilsgaard T. Hansen J.B. Alcohol consumption, types of alcoholic beverages and risk of venous thromboembolism - the Tromsø Study. *Thromb Haemost*. 2011; 106: 272-278.
119. Yuan S, Bruzelius M, Damrauer SM, Håkansson N, Wolk A, Åkesson A, Larsson SC. Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies. *Nutr Metab Cardiovasc Dis*. 2021 Sep 22;31(10):2831-2838. doi: 10.1016/j.numecd.2021.06.021.
120. Wu JM, Wang ZR, Hsieh TC, et al. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine, *Int J Mol Med*, 2001, vol. 8 1(pg. 3-17.
121. Shen CJ, Kao CH, Hsu TY, Chen CY, Lin CL, Shih HM. Effect of alcohol intoxication on the risk of venous thromboembolism: A nationwide retrospective cohort study. *Medicine (Baltimore)*. 2017;96(42):e8041. doi:10.1097/MD.00000000000008041.
122. Tanaka A, Cui R, Kitamura A, et al. Heavy alcohol consumption is associated with impaired endothelial function. *J Atheroscler Thromb* 2016;23:1047–54.
123. Ruf JC. Wine and polyphenols related to platelet aggregation and atherothrombosis. *Drugs Exp Clin Res* 1999;25:125–31.
124. Numminen H, Syrjala M, Benthin G, et al. The effect of acute ingestion of a large dose of alcohol on the hemostatic system and its circadian variation. *Stroke* 2000;31:1269–73.
125. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. *Arch Intern Med* 2003;163:2368–92.

126. Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. *Circulation* 2001;104:1367–73.
127. Smith FB, Lee AJ, Fowkes FG, et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. *Arterioscler Thromb Vasc Biol* 1997;17:3321–5.
128. Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. *Lancet* 1994;343:940–3.
129. Gonzalez-Reimers E, Santolaria-Fernandez F, Martin-Gonzalez MC, et al. Alcoholism: a systemic proinflammatory condition. *World J Gastroenterol* 2014;20:14660–71.
130. Petaja J. Inflammation and coagulation. An overview. *Thromb Res* 2011;127(Suppl 2):S34–7.
131. Jin M, Cai S, Guo J, et al. Alcohol drinking and all cancer mortality: a meta-analysis. *Ann Oncol* 2013;24:807–16.
132. Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. *J Trauma*. 1994;37:480–487. doi:10.1097/00005373-199409000-00025.
133. Phang M, Lazarus S, Wood LG, et al. Diet and thrombosis risk: nutrients for prevention of thrombotic disease, *Semin Thromb Hemost*, 2011, vol. 37 3(pg. 199-208.
134. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators, Ann Intern Med*, 2007, vol. 146 11(pg. 761-767.
135. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial, *Blood*, 2007, vol. 109 1(pg. 139-144)), <https://doi.org/10.1161/CIRCULATIONAHA.106.641688>.
136. Homocysteine Lowering Trialists' Collaboration Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials, *BMJ*, 1998, vol. 316 7135(pg. 894-898.
137. Bos GMJ, Heijer den M, Willems H, Blom H, Gerrits W, Cattaneo M, Eichinger S, Rosendaal F. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism: a first randomised, placebo-controlled, double-blind trial. *Blood*. 2004; 104: A489.
138. Booth SL, Golly I, Sackeck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status, *Am J Clin Nutr*, 2004, vol. 80 1(pg. 143-148.
139. Murohara T, Ikeda H, Otsuka Y, et al. Inhibition of platelet adherence to mononuclear cells by alpha-tocopherol: role of P-selectin, *Circulation*, 2004, vol. 110 2(pg. 141-148.
140. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study, *Circulation*, 2007, vol. 116 13(pg. 1497-1503.

141. Jacobs DR, Steffen LM. Nutrients, foods, and dietary patterns as exposures in research: issues and challenges. *Am J Clin Nutr.* 2003; 78 (suppl): 508S–513S.
142. Yi SY, Steffen LM, Lutsey PL, Cushman M, Folsom AR. Contrasting Associations of Prudent and Western Dietary Patterns with Risk of Developing Venous Thromboembolism. *Am J Med.* 2021 Jun;134(6):763-768.e3. doi: 10.1016/j.amjmed.2021.01.016.
143. Shen J, Wilmot KA, Ghasemzadeh N, Molloy DL, Burkman G, Mekonnen G, Gongora MC, Quyyumi AA, Sperling LS. Mediterranean Dietary Patterns and Cardiovascular Health. *Annu Rev Nutr.* 2015;35:425-49. doi: 10.1146/annurev-nutr-011215-025104.
144. Pignatelli P, Pastori D, Farcomeni A, Nocella C, Bartimoccia S, Vicario T, Bucci T, Carnevale R, Violi F. Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. *Clin Nutr.* 2015; 34:899–903. doi: 10.1016/j.clnu.2014.09.011.
145. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). *Am J Med.* 2002; 113: 636–642.
146. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR. High plasma concentration of factor VIIIc is a major risk for venous thromboembolism. *Thromb Haemost.* 2000; 83: 5–9.
147. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR. High plasma concentration of factor VIIIc is a major risk for venous thromboembolism. *Thromb Haemost.* 2000; 83: 5–9.
148. Mezzano D, Leighton F, Martinez C, Marshall G, Cuevas A, et al. Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. *Eur J Clin Nutr.* 2001; 55: 444–451.
149. Simpson-Yap S, Oddy WH, Taylor B, Lucas RM, Black LJ, Ponsonby AL, Blizzard L, van der Mei I; Ausimmune/AusLong Investigators Group. High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. *Mult Scler.* 2021 Jun;27(7):1112-1124. doi: 10.1177/1352458520943087.